Ambien

(Zolpidem)

ApprovedSmall molecule

Zolpidem is used to help people fall asleep at the beginning of the night. It's a short-term treatment for insomnia that works by slowing brain activity to allow sleep.[2] Ambien is currently approved and in use across 28 indications[4].[1]

Ambien is one of 615 small molecule programs targeting Obstructive Sleep Apnea. It is currently in Approved.

Indications

Total Trials

Active Trials

614

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Obstructive Sleep ApneaActive, not recruiting

CognitionActive, not recruiting

Progressive Supranuclear PalsyActive, not recruiting

CirrhosisActive, not recruiting

AgeActive, not recruiting

Depressive DisorderApproved

Prostate AdenocarcinomaApproved

Parkinson DiseaseApproved

Drug DependenceApproved

Low Back PainApproved

Obstructive Sleep ApneaApproved

Active, not recruiting

CognitionApproved

Active, not recruiting

Progressive Supranuclear PalsyApproved

Active, not recruiting

CirrhosisPreclinical

Active, not recruiting

AgePreclinical

Active, not recruiting

Depressive DisorderApproved

Approved

Prostate AdenocarcinomaApproved

Approved

Parkinson DiseaseApproved

Approved

Drug DependenceApproved

Approved

Low Back PainApproved

Approved

Showing 10 of 28 indications

Competition

Competitive Landscape

143 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Ambien

PPurdue Pharma LP

Approved

1 2

Cataflam

Bayer Aspirin

Enbrel

2 5

Glucophage

EMD Serono

Preclinical

1 6

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 7

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 8

Catapres

Boehringer Ingelheim

Preclinical

1 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 10

Chirocaine

PPurdue Pharma LP

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Recruiting

Orthopedic Trauma

NCT07336277

Q2 2028

Phase 2Recruiting

Autism

NCT05540574

Clinical

Trials by Indication[1]

Insomnia22 trials

An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00784875·643 enrolled

A Study of FK199B to Compare Efficacy With Zolpidem by Polysomnography in Patients With Insomnia

Completed· Astellas logo

Astellas·Phase 3·NCT00999219·55 enrolled

CBT-I or Zolpidem/Trazodone for Insomnia

Completed·—·Phase 4·NCT04468776·155 enrolled

Show 19 more trials

A Double-blind, Group-comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia

Completed· Astellas logo

Astellas·Phase 3·NCT00283946·876 enrolled

Sequenced Therapies for Comorbid and Primary Insomnias

Completed·—·N/A·NCT01651442·211 enrolled

Intranasal Dexmedetomidine and Zolpidem for Treatment of Primary Insomnia

Unknown status·TThe University of Hong Kong·Phase 3·NCT05615727·20 enrolled

Stilnox Treatment in Elderly Patients With Insomnia

Completed· Sanofi logo

Sanofi·Phase 4·NCT00359229·115 enrolled

Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia

Completed·MMidnight Pharma, LLC·Phase 3·NCT00608985·709 enrolled

Evaluation of the Hypnotic Properties of Zolpidem-MR 12.5 mg and Zolpidem 10 mg Marketed Product Compared to Placebo in Patients With Primary Insomnia

Completed· Sanofi logo

Sanofi·Phase 3·NCT00630175·113 enrolled

A Study of LY2624803 in Participants With Transient Insomnia

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01779830·32 enrolled

Zolpidem Postmarketing Study in Adolescent Patients With Insomnia

Completed· Astellas logo

Astellas·Phase 4·NCT00432198·122 enrolled

Efficacy and Safety Assessment of ZOlpidem (Stilnox CR) in Patients With Chronic insomNIA

Completed· Sanofi logo

Sanofi·Phase 4·NCT01024192·135 enrolled

Zolpidem (Myslee) Post Marketing Study in Adolescent Patients With Insomnia - Evaluation With Polysomnography

Completed· Astellas logo

Astellas·Phase 4·NCT00653562·11 enrolled

The Role of Partial Reinforcement in the Long Term Management of Insomnia

Completed·UUniversity of Pennsylvania·N/A·NCT00662155·129 enrolled

Characteristics of Sleep Patterns in Young Adults With and Without Insomnia

Completed·UUniversity of Pittsburgh·Phase 4·NCT00177216·69 enrolled

Alternative Dosing Regimens in the Pharmacotherapy of Insomnia

Terminated·PPhilipps University Marburg·Phase 3·NCT02139098·23 enrolled

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT03375203·365 enrolled

Behavioral and Pharmacological Treatment for Insomnia

Completed·LLaval University·Phase 4·NCT00042146·160 enrolled

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

Completed· Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.·Phase 2·NCT02839200·360 enrolled

Zolpidem or Exercise for Insomnia?

Completed·UUniversidade Federal de Goias·Phase 1·NCT03160404·34 enrolled

Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder

Completed· Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.·Phase 2·NCT03056053·113 enrolled

Biolab Zolpidem Orodispersible 1.0 mg, 1.75 mg and 3.5 mg to Treat Maintenance Insomnia Disorder.

Unknown status·BBiolab Sanus Farmaceutica·Phase 2/3·NCT03885141·366 enrolled

Sleep4 trials

Two Contrasting Interventions for Sleep Management

Completed·UUniversity of Utah·Phase 2/3·NCT01804036·72 enrolled

Sleepiness and the Risk of Falling

Completed·NNational Institute on Aging (NIA)·N/A·NCT00383357·24 enrolled

Disturbed Sleep Model Study.

Completed· GSK logo

GSK·Phase 1·NCT00440323·52 enrolled

Show 1 more trial

Sleep and Breathing in the General Population - Chemical Stimuli

Completed·WWayne State University·Phase 4·NCT04720547·14 enrolled

Abuse Potential4 trials

Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users

Completed·MMidnight Pharma, LLC·Phase 1·NCT01987739·42 enrolled

A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users

Completed· Eisai logo

Eisai·Phase 1·NCT03158025·39 enrolled

Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users

Completed· Idorsia Pharmaceuticals Ltd. logo

Idorsia Pharmaceuticals Ltd.·Phase 1·NCT03657355·63 enrolled

Show 1 more trial

A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT05106153·127 enrolled

Fasting Conditions4 trials

Zolpidem Tartrate 10 mg Tablets Under Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT00833521·38 enrolled

Zolpidem Tartrate 10 mg Tablets Under Non-Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT00833937·24 enrolled

Bioequivalence Study of Zolpidem 10mg Tablets Under Fasting Conditions

Completed·RRanbaxy Laboratories Limited·N/A·NCT00779051·36 enrolled

Show 1 more trial

Bioequivalency Study of Zolpidem Tartrate Under Fasting Conditions

Completed·RRoxane Laboratories·N/A·NCT00601666·30 enrolled

Sleep Disorder4 trials

The Study of Spectrum of Sleep Disorders in Cirrhotic Patients and the Efficacy of Zolpidem in Cirrhotic Patients With Insomnia

Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT02484963·52 enrolled

Improving Perioperative Sleep Disorders

Completed·MMengchang Yang·Phase 1·NCT06512155·215 enrolled

Z-Drugs for Sleep Disorders in Alzheimer's Disease

Completed·—·Phase 3·NCT03075241·62 enrolled

Show 1 more trial

Chinese Medicine Treatment of Adolescent Sleep Disorders and Sleeping Pills Withdrawal

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT06244277·106 enrolled

43 more indications

Memory3 trials

Memory Consolidation in Pharmacologically Enhanced Naps

Completed·UUniversity of California, San Diego·N/A·NCT00777829·30 enrolled

Hypnotic Medications and Memory: Effect of Drug Exposure During the Night

Completed·SSt. Luke's Hospital, Chesterfield, Missouri·Phase 4·NCT01159652·26 enrolled

Enhancing Memory Consolidation in Older Adults

Terminated·UUniversity of California, Irvine·Phase 4·NCT03657212·10 enrolled

Treatment2 trials

Long Term Treatment With Zolpidem: Nightly and Intermittent Dosing

Completed·UUniversity of Rochester·Phase 4·NCT00156533·20 enrolled

Effect Of Treatment With Oral Zolpidem On Polysomnography And Actigraphy Measures In Healthy Volunteers

Completed· Pfizer logo

Pfizer·Phase 1·NCT00716521·11 enrolled

Medication2 trials

Optimize Astronaut Sleep Medication Efficacy and Individual Effects

Completed·NNational Aeronautics and Space Administration (NASA)·Phase 4·NCT03526575·34 enrolled

The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep

Completed·JJohns Hopkins University·Phase 1·NCT00893269·36 enrolled

Single Dose2 trials

A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

Completed· Eisai logo

Eisai·Phase 1·NCT01463098·122 enrolled

Single Dose Pharmacokinetic and Pharmacodynamic Evaluation of Three Different Doses of Zolpidem in Children

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 1/2·NCT00494468·63 enrolled

Hip Fracture1 trial

Incidence of Delirium in Hip Fracture Patients Randomized to Regular Hypnotics vs Placebo

Terminated·HHvidovre University Hospital·Phase 4·NCT00286936·96 enrolled

Pilot Study1 trial

Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT02578472·36 enrolled

Satisfaction1 trial

Sleep Satisfaction and Psychomotor Performance of Adults

Completed· Sanofi logo

Sanofi·Phase 4·NCT01097382·30 enrolled

Parkinson's Disease1 trial

Use of Low-dose Zolpidem in Parkinson's Disease

Completed·—·Phase 2·NCT03621046·28 enrolled

ART1 trial

Bioequivalency Study of Zolpidem Tartrate Under Fed Conditions

Completed·RRoxane Laboratories·N/A·NCT00602719·30 enrolled

OSA1 trial

Zolpidem on CPAP Acclimatization in OSA

Unknown status·SSiriraj Hospital·Phase 4·NCT06084130·30 enrolled

Altitude1 trial

Hypnotic Intake and Motor and Cognitive Performances at High Altitude

Completed·CCentre d'Expertise sur l'Altitude EXALT·N/A·NCT02778659·22 enrolled

Endometrial Cancer1 trial

Sleep and Endometrial Cancer

Terminated·UUniversity of Pittsburgh·N/A·NCT00936598·6 enrolled

Premedication1 trial

A Comparison of Midazolam and Zolpidem as Oral Premedication in Children

Completed·LLoma Linda University·Phase 3·NCT02096900·86 enrolled

Melatonin1 trial

Study to Investigate the Effects of Melatonin, Temazepam & Zolpidem on Sleep EEG in Men and Women

Completed·UUniversity of Surrey·Phase 1·NCT00940550·16 enrolled

Interaction1 trial

Proton MRS Study of SSRI-Zolpidem Interactions

Completed·MMclean Hospital·Phase 1·NCT01809626·14 enrolled

Hot flashes1 trial

Estrogen for Treating Depression in Menopausal Women With Hot Flashes and Insomnia

Completed·—·Phase 4·NCT00227942·86 enrolled

Anxiolytic Effect1 trial

Sedative-Anxiolytic Effects on Simulated Driving Performance

Completed·MMarion Coe·Phase 4·NCT03297944·15 enrolled

Obstructive Sleep Apnea1 trial

Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 4·NCT00086281·60 enrolled

Orexin Antagonist1 trial

Effect of a Hypocretin/Orexin Antagonist on Neurocognitive Performance

Completed·NNorthern California Institute of Research and Education·N/A·NCT01243060·203 enrolled

Cycling1 trial

Zolpidem's Effects on Road Cycling Performance

Completed·—·Phase 4·NCT06800378·15 enrolled

Cannabis Use Disorder1 trial

The Role of Sleep in the Treatment of Cannabis Use Disorders

Completed·JJohns Hopkins University·Phase 2/3·NCT01685073·127 enrolled

Attention Deficit Hyperactivity Disorder1 trial

Efficacy, Safety, and Tolerability of Ambien (Zolpidem) in the Treatment of Children Ages 6 to 17 With Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

Completed· Sanofi logo

Sanofi·Phase 3·NCT00318448·201 enrolled

Fed1 trial

Bioequivalence Study of Zolpidem 10 mg Tablets Under Fed Conditions

Completed·RRanbaxy Laboratories Limited·N/A·NCT00779441·36 enrolled

Cognition1 trial

Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers

Completed·CCurrax Pharmaceuticals·Phase 4·NCT02353299·52 enrolled

Dexmedetomidine1 trial

Polysomnographic Study Comparing the Use of Dexmedetomidine and Zolpidem to Induce Natural Sleep

Completed·MMassachusetts General Hospital·N/A·NCT01485393·10 enrolled

Shoulder Arthroplasty1 trial

Multimodal Sleep Pathway for Shoulder Arthroplasty

Completed·UUniversity of California, San Francisco·Phase 1·NCT03269760·122 enrolled

Autism1 trial

Trial of Zolpidem for Sleep in Children With Autism

Recruiting·SStanford University·Phase 2·NCT05540574·26 enrolled

Menstrual Cycle1 trial

Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women

Completed·UUniversity of Pennsylvania·N/A·NCT00676026·8 enrolled

ESS1 trial

STILDEP: Zolpidem in Depressive and Dysthimic Patients

Completed· Sanofi logo

Sanofi·Phase 4·NCT00292734·120 enrolled

Imaging1 trial

Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T

Unknown status·MMclean Hospital·Phase 1·NCT01747590·12 enrolled

Postoperative Sleep Disturbance1 trial

Postoperative Sleep Disturbances After Zolpidem Treatment in Fast-track Hip and Knee Replacement

Unknown status·RRigshospitalet, Denmark·N/A·NCT01551485·20 enrolled

Osteoarthritis1 trial

Insomnia and Daytime Function in Osteoarthritis

Completed· Sanofi logo

Sanofi·Phase 4·NCT00530556·170 enrolled

Sleep Quality1 trial

Lavender vs Zolpidem Sleep Quality During Diagnostic PSG

Completed·HHealthPartners Institute·Phase 1·NCT04102345·58 enrolled

Focal Dystonia1 trial

Electrophysiological and Neuroimaging Correlates of the Effect of Zolpidem in Patients With Focal Dystonia

Completed·UUniversity Medical Centre Ljubljana·Phase 1·NCT04692285·24 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Chronic Hypnotic Use

Completed·HHenry Ford Health System··NCT01006525·116 enrolled

Double-blind1 trial

A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study

Active, not recruiting·WWalter Reed Army Institute of Research (WRAIR)·Phase 1·NCT04273776·90 enrolled

PK/PD1 trial

PK/PD Study of YZJ-1139

Completed·SShanghai Haiyan Pharmaceutical Technology Co., Ltd.·Phase 1·NCT06685341·20 enrolled

Efficacy1 trial

The Efficacy of Lower Dose Zolpidem for Achieving Satisfactory Sleep in Women With Disordered Sleep

Unknown status·RRhode Island Hospital··NCT03786120·50 enrolled

Progressive Supranuclear Palsy(PSP)1 trial

Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)

Completed·UUniversity of California, San Francisco·Approved·NCT04014387·40 enrolled

Orthopedic Trauma1 trial

Sleep Quality and the Efficacy of a Multimodal Sleep Pathway in Hospitalized Orthopedic Trauma Patients

Recruiting·EEmory University·Phase 3·NCT07336277·30 enrolled

Insomnia Disorder1 trial

A Randomized, Double-blind, Active-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of YZJ-1139 Tablets in the Treatment of Insomnia Disorder

Completed·SShanghai Haiyan Pharmaceutical Technology Co., Ltd.·Phase 3·NCT06975514·61 enrolled

Prostatic Neoplasms1 trial

A Pilot Study to Evaluate the Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT03436745·12 enrolled

Unspecified1 trial

Pharmacovigilance in Gerontopsychiatric Patients

Terminated·HHannover Medical School·Phase 3·NCT02374567·407 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 16, 1992

AMBIEN

NDA NDA019908

Dec 16, 1992

AMBIEN

NDA NDA019908

Jan 9, 1995

AMBIEN

NDA NDA019908

Jul 14, 1995

AMBIEN

NDA NDA019908

Oct 4, 1995

AMBIEN

NDA NDA019908

Apr 18, 1996

AMBIEN

NDA NDA019908

Dec 1, 1999

AMBIEN

NDA NDA019908

Apr 13, 2001

AMBIEN

NDA NDA019908

May 4, 2001

AMBIEN

NDA NDA019908

Nov 15, 2001

AMBIEN

NDA NDA019908

Jan 15, 2002

AMBIEN

NDA NDA019908

May 21, 2002

AMBIEN

NDA NDA019908

Sep 25, 2002

AMBIEN

NDA NDA019908

Sep 2, 2005

AMBIEN CR

NDA NDA021774

Sep 2, 2005

AMBIEN CR

NDA NDA021774

Mar 28, 2007

AMBIEN

NDA NDA019908

Apr 25, 2007

TOVALT ODT

NDA NDA021412

Oct 4, 2007

AMBIEN

NDA NDA019908

Oct 4, 2007

AMBIEN

NDA NDA019908

Oct 4, 2007

AMBIEN

NDA NDA019908

Dec 20, 2007

AMBIEN CR

NDA NDA021774

Dec 20, 2007

AMBIEN CR

NDA NDA021774

Dec 20, 2007

AMBIEN CR

NDA NDA021774

Dec 20, 2007

AMBIEN CR

NDA NDA021774

Dec 20, 2007

AMBIEN CR

NDA NDA021774

May 7, 2008

AMBIEN

NDA NDA019908

Dec 19, 2008

ZOLPIMIST

NDA NDA022196

Mar 13, 2009

EDLUAR

NDA NDA021997

Apr 14, 2010

AMBIEN

NDA NDA019908

Apr 14, 2010

AMBIEN CR

NDA NDA021774

Nov 23, 2011

INTERMEZZO

NDA NDA022328

Apr 19, 2013

AMBIEN

NDA NDA019908

Apr 19, 2013

AMBIEN CR

NDA NDA021774

Apr 19, 2013

AMBIEN

NDA NDA019908

Apr 19, 2013

AMBIEN CR

NDA NDA021774

Jun 5, 2013

AMBIEN

NDA NDA019908

Oct 7, 2014

AMBIEN

NDA NDA019908

Oct 7, 2014

AMBIEN CR

NDA NDA021774

Aug 11, 2016

AMBIEN CR

NDA NDA021774

Aug 11, 2016

AMBIEN

NDA NDA019908

Dec 2, 2016

AMBIEN

NDA NDA019908

Dec 2, 2016

AMBIEN CR

NDA NDA021774

Mar 3, 2017

AMBIEN CR

NDA NDA021774

Mar 3, 2017

AMBIEN

NDA NDA019908

Sep 14, 2018

AMBIEN

NDA NDA019908

Sep 14, 2018

AMBIEN CR

NDA NDA021774

Feb 6, 2019

AMBIEN

NDA NDA019908

Feb 6, 2019

AMBIEN CR

NDA NDA021774

Aug 18, 2019

AMBIEN CR

NDA NDA021774

Aug 18, 2019

AMBIEN

NDA NDA019908

Feb 23, 2022

AMBIEN

NDA NDA019908

Feb 23, 2022

AMBIEN

NDA NDA019908

Feb 23, 2022

AMBIEN CR

NDA NDA021774

Feb 23, 2022

AMBIEN CR

NDA NDA021774

Feb 23, 2022

AMBIEN CR

NDA NDA021774

Feb 23, 2022

AMBIEN

NDA NDA019908

May 9, 2023

ZOLPIDEM TARTRATE

NDA NDA215721

Sources

References

[1]
ClinicalTrials.gov — 86 trial records for Zolpidem. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Ambien drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Zolpidem compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Zolpidem. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA215721). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Ambien. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Purdue Pharma LP company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: GABA a Receptor Alpha-1/beta-1/gamma-2 Positive Allosteric Modulator[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: PPurdue Pharma LP

Patent Landscape[6]

Patent Cliff

Apr 6, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

9597281Apr 6, 2027

7658945Apr 15, 2027

8242131Aug 20, 2029

9265720Feb 25, 2031

8236285Aug 7, 2032

Ambien

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q2 2028

Trials by Indication[1]

Insomnia22 trials

Sleep4 trials

Abuse Potential4 trials

Fasting Conditions4 trials

Sleep Disorder4 trials

Memory3 trials

Treatment2 trials

Medication2 trials

Single Dose2 trials

Hip Fracture1 trial

Pilot Study1 trial

Satisfaction1 trial

Parkinson's Disease1 trial

ART1 trial

OSA1 trial

Altitude1 trial

Endometrial Cancer1 trial

Premedication1 trial

Melatonin1 trial

Interaction1 trial

Hot flashes1 trial

Anxiolytic Effect1 trial

Obstructive Sleep Apnea1 trial

Orexin Antagonist1 trial

Cycling1 trial

Cannabis Use Disorder1 trial

Attention Deficit Hyperactivity Disorder1 trial

Fed1 trial

Cognition1 trial

Dexmedetomidine1 trial

Shoulder Arthroplasty1 trial

Autism1 trial

Menstrual Cycle1 trial

ESS1 trial

Imaging1 trial

Postoperative Sleep Disturbance1 trial

Osteoarthritis1 trial

Sleep Quality1 trial

Focal Dystonia1 trial

Safety and Efficacy1 trial

Double-blind1 trial

PK/PD1 trial

Efficacy1 trial

Progressive Supranuclear Palsy(PSP)1 trial

Orthopedic Trauma1 trial

Insomnia Disorder1 trial

Prostatic Neoplasms1 trial

Unspecified1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News